CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
June 2nd, 2022
The CAM-Delam assay to evaluate the metastatic capacity of cancer cells is relatively fast, easy, and cheap. The method can be used for unraveling the molecular mechanisms regulating metastasis formation and for drug screening. An optimized assay for analyzing human tumor samples could be a clinical method for personalized cancer treatment.
Overview
The CAM-Delam assay is a rapid, cost-effective method for evaluating the metastatic capacity of cancer cells. This technique aids in understanding the molecular mechanisms of metastasis and can be utilized for drug screening and personalized cancer treatment.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Cell Biology
Background
- The CAM-Delam assay assesses the ability of cancer cells to delaminate and invade.
- It provides insights into the metastatic aggressiveness of cancer cells.
- The method is designed to be straightforward and efficient.
- Visual demonstrations enhance the understanding of the assay's technical steps.
Purpose of Study
- To evaluate the metastatic capacity of cancer cells.
- To unravel molecular mechanisms regulating metastasis formation.
- To facilitate drug screening for cancer treatments.
Methods Used
- Incubation of chick eggs to prepare for the assay.
- Preparation and sterilization of materials required for the assay.
- Culture of cancer cell lines and preparation of cell suspensions.
- Dissection and fixation of CAM-Delam samples for analysis.
Main Results
- The assay allows for visualization and quantification of cancer cell behavior.
- It provides a method to assess the metastatic potential of various cancer cells.
- Results can inform personalized treatment strategies for cancer patients.
- The method is efficient and reproducible for clinical applications.
Conclusions
- The CAM-Delam assay is a valuable tool for cancer research.
- It enhances understanding of metastasis and its underlying mechanisms.
- This method has potential clinical applications in personalized cancer therapy.
Frequently Asked Questions
Executive Industry Relevance
The CAM-Delam assay provides a standardized, quantitative platform for assessing metastatic potential by measuring cancer cell delamination and invasion in a biologically relevant system. This capability enables early-stage mechanistic de-risking and supports predictive confidence in target validation for metastasis-focused oncology portfolios. Integrating this assay into discovery workflows enhances the ability to triage candidate targets and compounds based on functional metastatic aggressiveness.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of metastatic mechanisms through quantifiable delamination and invasion readouts.
- Supports functional target validation by distinguishing aggressive from non-aggressive cancer cell phenotypes.
- Facilitates mechanistic de-risking by linking molecular interventions to metastatic behavior in a controlled system.
Screening & Assay Development
- Provides a reproducible, scalable assay for evaluating compound effects on metastatic processes.
- Delivers standardized scoring categories for robust comparison across cell lines and interventions.
- Enables quantitative assessment of basement membrane integrity and invasion, supporting downstream screening workflows.
Translational & Preclinical Research
- Aligns with disease-relevant metastatic biology, bridging discovery findings to preclinical model validation.
- Offers potential for translational biomarker development by correlating delamination capacity with metastatic risk.
- Supports risk-adjusted advancement decisions by providing functional evidence of metastatic modulation.
Pipeline & Workflow Integration
The CAM-Delam assay fits within the early discovery to preclinical continuum, enabling functional validation of metastatic targets and interventions prior to in vivo studies.
- Discovery Biology: Quantifies delamination and invasion as mechanistic endpoints for hypothesis testing and pathway clarification.
- Screening: Supplies reproducible, quantitative outputs for compound and genetic perturbation assessment.
- Analytics: Generates categorical and quantitative data on basement membrane status and cell invasion for comparative analysis.
- Translational Research: Provides a platform for aligning in vitro findings with in vivo metastatic potential when supported by further validation.
- Enterprise Reuse: Establishes a reusable assay framework for ongoing metastatic research and portfolio triage.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in metastatic target validation and reduces mechanistic ambiguity.
- Operational Value: Improves standardization, reproducibility, and scalability of metastasis assays.
- Strategic Value: Enables more informed go/no-go decisions and enhances capital efficiency by de-risking early-stage candidates.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of assets with validated anti-metastatic potential.
Implementation Considerations
- Requires expertise in cell culture, chick embryo handling, and immunohistochemistry.
- Needs access to cryosectioning, fluorescence microscopy, and quantitative image analysis infrastructure.
- Demands rigorous cross-team standardization of scoring and sample handling protocols.
- Adaptation to additional cancer models or clinical samples may require further optimization.
- Assay readouts depend on careful avoidance of technical artifacts such as membrane damage during cell seeding.
Biopharma FAQs
Chapters in this video
0:05
Introduction
1:00
Egg Incubation, Preparation of Weighing Boat, Plastic Boxes, and Dissection Instruments
1:46
Opening the Eggs, Transferring to the Internal Humidified Chamber, and Preparing Silicone Rings
3:07
Preparation and Seeding the Cancer Cells on the CAM
5:31
Isolation of the CAM with Associated Cancer Cells and Sectioning CAM-Delam Samples
7:28
Immunohistochemistry Staining, Microscopy Imaging, and Delamination Scoring
9:40
Results: CAM-Delam Assay to Evaluate the Metastatic Capacity of Cancer Cells
11:33
Conclusion
